24 April 2012 | News | By BioSpectrum Bureau
NZ Smart device company receives $2.5m fund
â€ŽSingapore: Asia Pacific healthcare fund manager, BioScience Managers have plans to make investment of US$2.5 million (NZ$2 million) in innovative New Zealand asthma technology company Nexus6.
Nexus6's SmartInhaler product remotely monitors adherence to asthma treatment regimes, ensuring patients comply with treatment protocols in general use and in clinical trials, giving clinicians transparency over inhaler use and dosage in real time.
"Nexus6 technology holds the key to not only ensuring better patient outcomes, but also in minimising wastage and costs of treatment, by ensuring that asthma sufferers take only what they need and when they need it," said BioScience Managers Managing Director, Mr. Jeremy Curnock Cook.
The Smartinhaler range allows physicians and patients to monitor real life use of inhaled treatments for respiratory conditions. This means that physicians can remotely ensure that patients are adhering to the optimal treatment program for their condition.
Over the past 10 years, the company has invested heavily in the development of its core Smartinhaler platform for use with inhaled respiratory medications and has successfully sold its products to large international pharmaceutical companies for use in clinical trials. This new investment will enable Nexus6 to accelerate international expansion and significantly increase its sales and marketing capabilities.
Nexus6 founder Garth Sutherland commented, "The combination of capital to execute our growth strategy and the experienced support of the BioScience Managers team provides us with a unique opportunity to take our company global.
"Smartinhaler represents a new paradigm in the management of asthma and respiratory diseases. We now have the resources to take this product to the world and continue to build Nexus6 into an international leader in remote patient monitoring solutions."
Nexus6 marks BioScience Managers' second investment from its Asia Pacific Healthcare Fund II. "Nexus6 technology holds the key to not only ensuring better patient outcomes but also in minimising wastage and costs of treatment. It ensures patients with respiratory conditions take what they need and when they need it," said Bioscience Managers Managing Director, Jeremy Curnock Cook.